At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 19 enrolled
Drug / intervention
AZD2171drug
Likely dose
Not stated in record
Key inclusion· 4
- ✓Histologically or cytologically confirmed head and neck cancer (HNC)
- ✓Unresectable stage IIIb or IV non-small cell lung cancer (NSCLC)
- ✓At least one lesion able to be used for tumor biopsy and measurable by FDG-PET Scan
- ✓Considered suitable for treatment with no prior biological or immunological therapy for disease (NSCLC or HNC)
Key exclusion· 9
- ✕NSCLC: More than 2 previous chemotherapy regimens
- ✕NSCLC or HNC: Chemotherapy or radiotherapy within 28 days of first dose of AZD2171
- ✕Untreatable, unstable brain or meningeal metastases
- ✕Abnormal liver and kidney blood chemistries
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory, Open-Lael Study to Assess the Effects of AZD2171 on Tumors and Biomarkers in Patients With Previously Untreated or Recurrent Non-small Cell Lung Cancer (NSCLC) or Patients With Metastatic or Recurrent Head and Neck Cancer (HNC)
In Brief
A Phase 1 clinical trial evaluating AZD2171 for Carcinoma and 2 related conditions. Completed, enrolled 19 participants across 2 sites in 2 countries.
Detailed Summary
This study is to examine the effects on tumors of AZD2171, in the treatment of NSCLC or HNC. The safety and tolerability of AZD2171 will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSpain, United States
Collaborators--
Timeline
Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2005
Enrollment StartDec 2005
Primary CompletionMay 2008
Study CompletionJul 2009
TodayJul 2026
First PostedOct 24, 2005
Enrollment StartDec 1, 2005
Primary CompletionMay 1, 2008
Study CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 20.7 years ago
Interventions
AZD2171drug
oral tablet